RIPOR3

Summary

RIPOR3 (RIPOR family member 3, HGNC:16168) is a protein-coding gene on chromosome 20q13.13, encoding RIPOR family member 3 (Q96MK2).

At a glance

• GWAS associations: 6
• Clinical variants (ClinVar): 234 total
• MANE Select transcript: NM_001290268

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:16168
Approved symbol	RIPOR3
Name	RIPOR family member 3
Location	20q13.13
Locus type	gene with protein product
Status	Approved
Aliases	dJ530I15.2, dJ530I15.3
Ensembl gene	ENSG00000042062
Ensembl biotype	protein_coding
Entrez	140876

Gene structure

Transcript identifiers

Ensembl transcripts: 16 — 12 protein_coding, 3 protein_coding_CDS_not_defined, 1 retained_intron

ENST00000045083, ENST00000327979, ENST00000462493, ENST00000462842, ENST00000482129, ENST00000488529, ENST00000904041, ENST00000904042, ENST00000904043, ENST00000904044, ENST00000904045, ENST00000904046, ENST00000922749, ENST00000952574, ENST00000952575, ENST00000952576

RefSeq mRNA: 2 — MANE Select: NM_001290268 NM_001290268, NM_080829

CCDS: CCDS13431, CCDS93056

Canonical transcript exons

ENST00000327979 — 22 exons

Exon	Start	End
ENSE00001039309	50597580	50597710
ENSE00001523669	50586108	50587332
ENSE00001523671	50691126	50691542
ENSE00001523676	50589686	50589769
ENSE00001523678	50594553	50594714
ENSE00003481141	50608613	50608738
ENSE00003513433	50604645	50604774
ENSE00003529596	50593035	50593196
ENSE00003544423	50587802	50587892
ENSE00003548645	50596140	50596263
ENSE00003557041	50609293	50609356
ENSE00003562516	50616002	50616080
ENSE00003604592	50602072	50602644
ENSE00003607204	50608912	50608955
ENSE00003621982	50610853	50610906
ENSE00003633791	50608389	50608534
ENSE00003650206	50609573	50609722
ENSE00003664151	50619986	50620132
ENSE00003673064	50611181	50611204
ENSE00003676435	50592344	50592546
ENSE00003693810	50595369	50595504
ENSE00003841871	50630738	50630856

Expression profiles

Bgee: expression breadth ubiquitous, 190 present calls, max score 96.04.

FANTOM5 (CAGE): breadth broad, TPM avg 4.0573 / max 351.5298, expressed in 648 samples.

FANTOM5 promoters (12 alternative TSS)

Promoter ID	TPM avg	Samples expressed
187873	1.6110	115
187877	0.9373	368
187874	0.5683	91
187875	0.2484	102
187878	0.2304	134
187876	0.1564	76
187879	0.0808	33
187866	0.0739	17
187868	0.0494	25
187869	0.0454	25

Top tissues by expression

243 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
endocervix	UBERON:0000458	96.04	gold quality
metanephros cortex	UBERON:0010533	95.90	gold quality
left uterine tube	UBERON:0001303	95.57	gold quality
body of uterus	UBERON:0009853	94.46	gold quality
apex of heart	UBERON:0002098	93.73	gold quality
oocyte	CL:0000023	92.69	gold quality
omental fat pad	UBERON:0010414	91.99	gold quality
mucosa of stomach	UBERON:0001199	91.93	gold quality
peritoneum	UBERON:0002358	91.88	gold quality
ectocervix	UBERON:0012249	91.80	gold quality
adipose tissue of abdominal region	UBERON:0007808	90.84	gold quality
kidney epithelium	UBERON:0004819	89.81	gold quality
uterine cervix	UBERON:0000002	89.57	gold quality
right adrenal gland cortex	UBERON:0035827	89.45	gold quality
heart left ventricle	UBERON:0002084	89.02	gold quality
cardiac ventricle	UBERON:0002082	88.63	gold quality
right adrenal gland	UBERON:0001233	88.55	gold quality
adrenal cortex	UBERON:0001235	88.50	gold quality
left adrenal gland cortex	UBERON:0035825	88.16	gold quality
right lobe of liver	UBERON:0001114	88.03	gold quality
subcutaneous adipose tissue	UBERON:0002190	87.69	gold quality
lower esophagus muscularis layer	UBERON:0035833	87.65	gold quality
lower esophagus	UBERON:0013473	87.59	gold quality
left adrenal gland	UBERON:0001234	87.45	gold quality
right ovary	UBERON:0002118	87.29	gold quality
small intestine Peyer’s patch	UBERON:0003454	86.99	gold quality
secondary oocyte	CL:0000655	86.90	gold quality
right uterine tube	UBERON:0001302	86.87	gold quality
vagina	UBERON:0000996	86.69	gold quality
adrenal gland	UBERON:0002369	86.65	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-GEOD-75367	yes	1931.33
E-ANND-3	yes	12.54

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

36 targeting RIPOR3, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-499A-5P	99.98	70.79	1323
HSA-MIR-205-3P	99.92	69.92	3165
HSA-MIR-8087	99.90	69.55	1351
HSA-MIR-4496	99.88	68.89	2236
HSA-MIR-3140-3P	99.88	68.47	2069
HSA-MIR-4492	99.87	68.25	3611
HSA-MIR-3065-3P	99.87	70.25	1407
HSA-MIR-6817-3P	99.79	68.35	2126
HSA-MIR-8084	99.73	69.57	1760
HSA-MIR-6762-3P	99.66	66.94	1188
HSA-MIR-3609	99.52	69.89	2587
HSA-MIR-548AH-5P	99.52	69.73	2626
HSA-MIR-1912-3P	99.32	67.40	936
HSA-MIR-122B-3P	99.21	68.90	1333
HSA-MIR-21-3P	99.21	68.95	1312
HSA-MIR-6852-5P	99.17	66.69	2073
HSA-MIR-6815-3P	99.13	68.98	1530
HSA-MIR-4254	99.11	65.15	1315
HSA-MIR-6738-3P	99.03	67.14	1326
HSA-MIR-939-3P	98.97	65.07	2347
HSA-MIR-3926	98.95	69.26	1438
HSA-MIR-5001-3P	98.91	67.28	1394
HSA-MIR-4656	98.79	66.22	1306
HSA-MIR-198	98.70	67.32	920
HSA-MIR-4718	98.55	68.61	814
HSA-MIR-3187-5P	98.36	65.74	1776
HSA-MIR-3664-3P	97.85	67.62	1452
HSA-MIR-1285-3P	97.72	67.02	1932
HSA-MIR-5189-5P	97.72	66.96	1814
HSA-MIR-6860	97.21	66.31	1656

Literature-anchored findings (GeneRIF, showing 1)

• Downregulated Expression of RIPOR3 Correlated with Immune Infiltrates Predicts Poor Prognosis in Oral Tongue Cancer. (PMID:35277469)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	ripor3	ENSDARG00000020979
mus_musculus	Ripor3	ENSMUSG00000074577
rattus_norvegicus	Ripor3	ENSRNOG00000010791
caenorhabditis_elegans		WBGENE00045063

Paralogs (2): RIPOR1 (ENSG00000039523), RIPOR2 (ENSG00000111913)

Protein

Protein identifiers

RIPOR family member 3 — Q96MK2 (reviewed: Q96MK2)

All UniProt accessions (2): A0A499FJE4, Q96MK2

UniProt curated annotations — full annotation on UniProt →

Similarity. Belongs to the RIPOR family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q96MK2-1	1	yes
Q96MK2-2	2

RefSeq proteins (2): NP_001277197, NP_543019 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR026136	RIPOR3	Family
IPR031780	FAM65_N	Domain

Pfam: PF15903

UniProt features (16 total): modified residue 6, compositionally biased region 3, sequence variant 2, sequence conflict 2, chain 1, region of interest 1, splice variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q96MK2-F1	69.66	0.24

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (6): 384, 9, 24, 340, 345, 351

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 67 (showing top): WONG_ENDMETRIUM_CANCER_DN, MODULE_301, SCHAEFFER_PROSTATE_DEVELOPMENT_48HR_UP, CREIGHTON_ENDOCRINE_THERAPY_RESISTANCE_5, CERVERA_SDHB_TARGETS_1_UP, CHARAFE_BREAST_CANCER_LUMINAL_VS_MESENCHYMAL_UP, MASSARWEH_TAMOXIFEN_RESISTANCE_UP, NIKOLSKY_BREAST_CANCER_20Q12_Q13_AMPLICON, CHEN_METABOLIC_SYNDROM_NETWORK, STAMBOLSKY_TARGETS_OF_MUTATED_TP53_DN, DUTERTRE_ESTRADIOL_RESPONSE_24HR_DN, EIF4E_UP, CHARAFE_BREAST_CANCER_LUMINAL_VS_BASAL_UP, CBX5_TARGET_GENES, FOXN3_TARGET_GENES

GO Biological Process (0):

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (0):

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
binding	1

Protein interactions and networks

STRING

928 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
RIPOR3	HSD17B13	Q7Z5P4	447
RIPOR3	SUSD1	Q6UWL2	422
RIPOR3	EFCAB5	A4FU69	410
RIPOR3	LTC4S	Q16873	410
RIPOR3	ERICH6	Q7L0X2	404
RIPOR3	TRAPPC13	A5PLN9	381
RIPOR3	VSIG8	P0DPA2	377
RIPOR3	ANKIB1	Q9P2G1	377
RIPOR3	NSRP1	Q9H0G5	376
RIPOR3	PBDC1	Q9BVG4	374
RIPOR3	TAGAP	Q8N103	366
RIPOR3	AADACL3	Q5VUY0	365
RIPOR3	DPH6	Q7L8W6	351
RIPOR3	TMPRSS11E	Q9UL52	349
RIPOR3	TMEM72	A0PK05	345

IntAct

20 interactions, top by confidence:

A	B	Type	Score
RHOA	RIPOR3	psi-mi:“MI:0915”(physical association)	0.670
RIPOR3	SHANK2	psi-mi:“MI:0915”(physical association)	0.560
CCDC125	RIPOR3	psi-mi:“MI:0915”(physical association)	0.560
TRAF1	RIPOR3	psi-mi:“MI:0915”(physical association)	0.560
RHOC	RIPOR3	psi-mi:“MI:0915”(physical association)	0.560
SCML4	RIPOR3	psi-mi:“MI:0915”(physical association)	0.560
RIPOR3	AIP	psi-mi:“MI:0914”(association)	0.350
RIPOR3	RHOC	psi-mi:“MI:0915”(physical association)	0.000
RIPOR3	SHANK2	psi-mi:“MI:0915”(physical association)	0.000
RIPOR3	CCDC125	psi-mi:“MI:0915”(physical association)	0.000
RIPOR3	TRAF1	psi-mi:“MI:0915”(physical association)	0.000
RHOA	RIPOR3	psi-mi:“MI:0915”(physical association)	0.000
RIPOR3	SCML4	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (11): TRAF1 (Two-hybrid), RHOA (Two-hybrid), SCML4 (Two-hybrid), RHOC (Two-hybrid), SHANK2 (Two-hybrid), CCDC125 (Two-hybrid), SLC9A3R2 (Affinity Capture-MS), SLC9A3R1 (Affinity Capture-MS), SRPK3 (Affinity Capture-MS), AIP (Affinity Capture-MS), RHOA (Affinity Capture-MS)

ESM2 similar proteins: A0JNQ6, A6NC42, A6NGQ2, A6NGR9, A6QP75, A7E3N7, A9X185, E1BDF2, E9PGG2, F6SZT2, P0C7A0, P85965, Q06VW1, Q0ZFW8, Q14DK4, Q3UK37, Q3UV16, Q3ZBN4, Q400G9, Q4VXA5, Q587J8, Q5JSQ8, Q60953, Q60I26, Q60I27, Q6NUI2, Q6ZUX3, Q810I0, Q8BH06, Q8C0R7, Q8IWB1, Q8IWY9, Q8IYX4, Q8K4C2, Q8N6L0, Q8N7F7, Q8NCV1, Q8TE82, Q91WA6, Q95JV3

Diamond homologs: A1L3T7, A9ZLX4, Q1LU99, Q3B7M3, Q4FZU8, Q5EB20, Q5F3L9, Q68FE6, Q6ZS17, Q7TP54, Q80U16, Q96MK2, Q9Y4F9, O46119, O46414, O46415, O65100, P02791, P02792, P02793, P02794, P07229, P07797, P07798, P08267, P09451, P09528, P0C7X4, P17663, P18685, P18686, P19130, P19132, P19133, P19975, P19976, P25319, P25320, P25699, P25915

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

234 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	200
Likely benign	17
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

5350 predictions. Top by Δscore:

Variant	Effect	Δscore
20:50589680:GCTCA:G	donor_loss	1.0000
20:50589681:CTCA:C	donor_loss	1.0000
20:50589682:TCA:T	donor_loss	1.0000
20:50589683:CACCT:C	donor_loss	1.0000
20:50589684:A:T	donor_loss	1.0000
20:50589685:C:CA	donor_loss	1.0000
20:50592339:CGTA:C	donor_loss	1.0000
20:50592340:GTA:G	donor_loss	1.0000
20:50592343:C:A	donor_loss	1.0000
20:50592542:TGTCA:T	acceptor_gain	1.0000
20:50592543:GTCA:G	acceptor_gain	1.0000
20:50592544:TCA:T	acceptor_gain	1.0000
20:50592545:CA:C	acceptor_gain	1.0000
20:50592545:CAC:C	acceptor_gain	1.0000
20:50592546:ACT:A	acceptor_loss	1.0000
20:50592547:C:CC	acceptor_gain	1.0000
20:50592547:CTAG:C	acceptor_loss	1.0000
20:50592548:T:G	acceptor_loss	1.0000
20:50593030:CTTA:C	donor_loss	1.0000
20:50593031:TTA:T	donor_loss	1.0000
20:50593032:TACCT:T	donor_loss	1.0000
20:50593033:ACC:A	donor_loss	1.0000
20:50593033:ACCTT:A	donor_gain	1.0000
20:50593034:CCTT:C	donor_gain	1.0000
20:50593034:CCTTC:C	donor_gain	1.0000
20:50593037:T:A	donor_gain	1.0000
20:50593193:CACG:C	acceptor_gain	1.0000
20:50593195:CG:C	acceptor_gain	1.0000
20:50593197:C:CC	acceptor_gain	1.0000
20:50593202:C:CT	acceptor_gain	1.0000

AlphaMissense

6148 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
20:50608393:A:G	W314R	0.998
20:50608393:A:T	W314R	0.998
20:50608410:A:G	L308P	0.998
20:50608669:A:G	W248R	0.998
20:50608669:A:T	W248R	0.998
20:50608404:A:G	L310P	0.996
20:50608952:A:G	L211S	0.996
20:50610865:A:C	F134L	0.996
20:50610865:A:T	F134L	0.996
20:50610867:A:G	F134L	0.996
20:50608391:C:A	W314C	0.995
20:50608391:C:G	W314C	0.995
20:50608412:C:A	K307N	0.995
20:50608412:C:G	K307N	0.995
20:50608667:C:A	W248C	0.995
20:50608667:C:G	W248C	0.995
20:50608711:A:G	W234R	0.995
20:50608711:A:T	W234R	0.995
20:50608392:C:G	W314S	0.994
20:50608414:T:C	K307E	0.993
20:50608699:C:G	G238R	0.993
20:50608917:A:C	Y223D	0.993
20:50608934:A:G	L217P	0.993
20:50608410:A:T	L308Q	0.992
20:50608698:C:T	G238D	0.992
20:50619989:A:G	L85P	0.992
20:50608922:T:A	D221V	0.991
20:50608922:T:G	D221A	0.991
20:50610878:C:G	R130P	0.991
20:50608410:A:C	L308R	0.990

dbSNP variants (sampled 300 via entrez): RS1000036390 (20:50612329 C>G,T), RS1000077916 (20:50614377 G>A), RS1000078272 (20:50601870 A>T), RS1000160007 (20:50641228 G>A,T), RS1000173448 (20:50666522 C>A), RS1000184305 (20:50646032 C>G,T), RS1000198466 (20:50651803 G>A,T), RS1000205538 (20:50627760 G>A), RS1000267970 (20:50657490 G>A), RS1000326649 (20:50692294 G>A,C), RS1000371848 (20:50633555 T>G), RS1000376050 (20:50686388 G>A), RS1000409345 (20:50686447 A>C,G), RS1000436654 (20:50692050 T>A,C), RS1000470571 (20:50638650 G>C,T)

Disease associations

OMIM: gene `` | disease phenotypes:

GenCC curated gene-disease

Mondo (1): prostate cancer (MONDO:0008315)

Orphanet (1): Familial prostate cancer (Orphanet:1331)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

6 associations (top):

Study	Trait	p-value
GCST009391_152	Metabolite levels	1.000000e-06
GCST010083_104	Hemoglobin levels	1.000000e-08
GCST012490_639	Femur bone mineral density x serum urate levels interaction	4.000000e-09
GCST90002388_582	Lymphocyte count	4.000000e-19
GCST90002401_325	Platelet distribution width	2.000000e-10
GCST90002407_176	White blood cell count	2.000000e-14

EFO canonical traits (5, from GWAS)

EFO ID	Trait name
EFO:0010486	glucuronate measurement
EFO:0004509	hemoglobin measurement
EFO:0004531	urate measurement
EFO:0004587	lymphocyte count
EFO:0007984	platelet component distribution width

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D011471	Prostatic Neoplasms	C04.588.945.440.770; C12.100.500.260.750; C12.100.500.565.625; C12.200.294.260.750; C12.200.294.565.625; C12.200.758.409.750; C12.900.619.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

27 total (human), top 27 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
methylmercuric chloride	decreases expression	2
bisphenol A	decreases expression, decreases methylation	2
Calcitriol	decreases expression, increases expression	2
Aflatoxin B1	decreases methylation, increases methylation	2
aristolochic acid I	increases expression	1
2,5,2’,5’-tetrachlorobiphenyl	decreases expression	1
aflatoxin B2	increases methylation	1
S-(1,2-dichlorovinyl)cysteine	affects response to substance, increases expression, affects cotreatment, decreases expression	1
licochalcone B	increases expression	1
bisphenol S	decreases expression	1
bisphenol AF	decreases expression	1
2,3,5-trichloro-6-phenyl-(1,4)benzoquinone	decreases expression	1
Zoledronic Acid	decreases expression	1
Leflunomide	increases expression	1
Atrazine	increases expression	1
Benzo(a)pyrene	affects expression	1
Dexamethasone	increases expression	1
Lipopolysaccharides	decreases expression, affects response to substance, increases expression, affects cotreatment	1
Nickel	increases expression	1
Oxygen	affects expression	1
Smoke	increases expression	1
Tetrachlorodibenzodioxin	increases expression	1
Tobacco Smoke Pollution	decreases expression	1
Valproic Acid	affects expression	1
7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide	increases expression	1
Okadaic Acid	decreases expression	1
Lactic Acid	decreases expression	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00029224	PHASE4	COMPLETED	Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
NCT00035997	PHASE4	COMPLETED	Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
NCT00063609	PHASE4	COMPLETED	The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
NCT00103623	PHASE4	SUSPENDED	The Plenaxis® Experience Study
NCT00106392	PHASE4	COMPLETED	A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy
NCT00185029	PHASE4	UNKNOWN	MR-Lymphography and Lymph Node Staging in Prostate Cancer
NCT00199485	PHASE4	COMPLETED	Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer
NCT00219219	PHASE4	COMPLETED	Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases
NCT00219271	PHASE4	COMPLETED	Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
NCT00237146	PHASE4	COMPLETED	Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
NCT00242554	PHASE4	COMPLETED	Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases
NCT00280098	PHASE4	COMPLETED	Docetaxel in the Treatment of Hormone Refractory Prostate Cancer
NCT00293696	PHASE4	COMPLETED	Casodex/Zoladex Biomarkers in Localised Prostate Cancer
NCT00334139	PHASE4	COMPLETED	Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
NCT00375765	PHASE4	COMPLETED	Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
NCT00391690	PHASE4	COMPLETED	Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
NCT00422708	PHASE4	COMPLETED	Local Anesthesia for Prostate Biopsy
NCT00526331	PHASE4	COMPLETED	Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy
NCT00590213	PHASE4	COMPLETED	Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX
NCT00629330	PHASE4	TERMINATED	Dissemination of Prostate Cancer Screening to PCP’s in African American Communities
NCT00771966	PHASE4	COMPLETED	Radical Prostatectomy and Perioperative Fluid Therapy
NCT00805701	PHASE4	COMPLETED	Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation
NCT00859027	PHASE4	COMPLETED	Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
NCT00906269	PHASE4	UNKNOWN	Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer
NCT00953277	PHASE4	COMPLETED	Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer
NCT00982800	PHASE4	COMPLETED	Does Postoperative Gabapentin Reduce Pain, Opioid Consumption and Anxiety and Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy?
NCT01083199	PHASE4	COMPLETED	Global Performance Evaluation of the AMS CONTINUUM™ Device
NCT01136226	PHASE4	COMPLETED	Evaluate Recovery of Testosterone for Patients Using Eligard
NCT01161563	PHASE4	COMPLETED	Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
NCT01230905	PHASE4	COMPLETED	Study to Monitor the Effects of Androgen Suppression Treatment on the Heart
NCT01296672	PHASE4	COMPLETED	3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer
NCT01365143	PHASE4	TERMINATED	Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy
NCT01379742	PHASE4	UNKNOWN	Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy
NCT01486563	PHASE4	COMPLETED	Hydroxyethyl Starch and Renal Function After Radical Prostatectomy
NCT01511874	PHASE4	COMPLETED	Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer
NCT01512472	PHASE4	TERMINATED	Firmagon (Degarelix) Intermittent Therapy
NCT01547416	PHASE4	COMPLETED	The Effect of Combined General/Epidural Anesthesia Versus General Anesthesia on Diaphragmatic Function
NCT01571544	PHASE4	COMPLETED	The Use of Thermal Suits as Preventing Hypothermia During Surgery
NCT01581749	PHASE4	UNKNOWN	Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer
NCT01649635	PHASE4	COMPLETED	Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer